Epitalon
Soviet-era tetrapeptide investigated for telomerase and circadian effects.
- Primary research area
- Longevity / circadian
- Last updated
- Apr 21, 2026
- Reviewed by
- Peptide Examiner editorial team
What it is
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, based on the natural pineal-gland peptide epithalamin. It is marketed heavily in biohacker circles as a longevity peptide and telomerase activator. It is not FDA approved. Research is overwhelmingly Russian-language and concentrated in a small number of research groups.
Mechanism of action
Epitalon is reported in Russian-language literature to activate telomerase in somatic cells, normalize circadian melatonin secretion, and influence the pineal gland's function. Proposed mechanisms at the molecular level involve interactions with DNA methylation, gene-expression modulation in specific promoter regions, and telomeric biology. The telomerase claim is the central marketing lever.
Research history
Russian clinical literature stretches back to the 1970s work on epithalamin (the natural parent peptide) and later epitalon (the synthetic analog). Reports include longevity effects in various animal models and observational human studies claiming reduced mortality and improved circadian function in elderly populations. Western independent replication of these findings is minimal; the evidence base is geographically concentrated and methodologically heterogeneous.
Current trial status
No active FDA-track clinical trials. Not an FDA investigational product.
Regulatory status
Not FDA approved. FDA Category 2 (September 2023). Feb 2026 HHS proposed removal. Research-use-only sales. Full regulatory timeline →
Controversies and open questions
Epitalon is a case study in how a substance can accumulate decades of claimed benefits without producing the caliber of evidence needed for Western regulatory approval. The telomerase-activation claim is particularly contested — rigorous independent verification at the biochemical level in human cells is limited. Claims of life-extension effects in humans outrun the published data substantially.
Further reading
Frequently asked
Does epitalon actually extend lifespan?
Human lifespan-extension evidence is effectively absent. Animal studies and Russian observational data in elderly populations report effects, but rigorous controlled human trials at the scale needed to answer the question haven't been conducted.
Does it activate telomerase?
The telomerase-activation claim is central to the marketing. The biochemical evidence is mixed — some cell-culture studies support it, but independent replication outside the originating Russian research group is limited.
Is it legal in the US?
No. FDA Category 2 (September 2023). February 2026 HHS proposed removal pending FDA review. Not FDA approved anywhere; Russian pharmacy-approved for specific elderly populations.
Why is so much of the research in Russian?
Epitalon was developed at the St. Petersburg Institute of Bioregulation and Gerontology and the corpus is heavily concentrated in that research lineage. Western independent replication is sparse, which limits the evidence base's credibility under FDA review standards.